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A critique of the overfill hypothesis of sodium and water retention in
the nephrotic syndrome. Recent reviews have claimed that the majority of
patients with the nephrotic syndrome have plasma volume expansion (that
is, they are overfilled). Here we attempt to re-establish balance to the
debate on body fluid volume status in nephrotic patients by: (a) discussing
the conflicting literature on plasma volume measurements in the nephrotic
syndrome; (b) providing alternate explanations for data purporting to
support an overfill hypothesis in the nephrotic syndrome; (c) emphasizing
secondary neurohumoral responses that support underfilling at least as
frequently as overfilling; and (d) emphasizing the clinical importance of
fluid assessment in the individual patient with the nephrotic syndrome
particularly in relation to diuretic use.
A recent scholarly review has emphasized that, “edema forma-
tion in the majority of patients with the nephrotic syndrome can
be best explained by an overfill mechanism” [1]. There can be
little doubt that some patients with nephrotic syndrome, particu-
larly those with associated renal failure, become volume expanded
and hypertensive concomitantly with an associated suppression of
the renin-angiotensin-aldosterone system [2]. These patients have
been referred to as having hypervolemic nephrotic syndrome (that
is, their circulations are overfilled). Patients with chronic renal
failure of various etiologies without nephrotic syndrome also
retain sodium and water, develop hypertension and respond
favorably to loop diuretics. These patients, however, demonstrate
substantial renal dysfunction. Patients with the nephrotic syn-
drome generally do not have the signs of volume expansion [3],
nor the very low renin and high atrial natriuretic peptide (ANP)
levels seen in acute glomerulonephritis [4]. What has been
suggested in patients with nephrotic syndrome is that intrarenal
mechanisms enhance tubular sodium reabsorption, mainly in the
distal tubule, and this effect predominates over extrarenal volume
regulatory mechanisms. These patients, therefore, become plasma
volume expanded (overfilled) in the presence of preserved renal
function as assessed by a normal, or near normal, glomerular
filtration rate (GFR). The purpose of this article is not to provide
another comprehensive review of the nephrotic syndrome, but
rather to critically assess some of the published results that have
been used to support the “overfill” hypothesis. Alternative inter-
pretations of these results are entertained in an effort to provide
some perspective about whether the “majority” patients with the
nephrotic syndrome are indeed plasma volume expanded.
PLASMA VOLUME MEASUREMENTS
One group of investigators has performed several studies over
the past 18 years that suggest that plasma volume is consistently
expanded in children and adults with nephrotic syndrome, includ-
ing those with minimal change disease [5–10]. There have been,
however, studies by other investigators who have demonstrated a
decrease in blood volume in patients with the nephrotic syndrome
[11–16]. If overfill mechanisms predominate, then the majority of
patients with nephrotic syndrome should have expanded plasma
volumes. In this regard, however, an analysis of 217 nephrotic
patients from 10 studies found that only 25% had expanded
plasma volumes [10]. This analysis does not, therefore, support
the overfill hypothesis for the majority of patients with nephrotic
syndrome. Interestingly, the results of these 10 studies mimic a
Gaussian distribution with 33% of patients demonstrating a
reduced plasma volume, 42% a normal plasma volume, and 25%
an increased plasma volume. It is, therefore, possible that plasma
volume measurements are not sufficiently sensitive to distinguish
between overfill and underfill mechanisms in the nephrotic syn-
drome. Measurements used to assess plasma volume in the
nephrotic syndrome have frequently utilized albumin as a tracer.
Since the initial whole body disappearance of albumin in humans
is biphasic and rapid, the “uncritical use of albumin as a plasma
volume marker is not justified” [17]. Thus, a larger tracer such as
fibrinogen could produce more reliable results, but this technique
has not yet been used in the nephrotic syndrome. In general, the
reproducibility of current techniques to measure plasma volume
varies by 6 10%, a range where renal sodium excretion is clearly
regulated by extrarenal mechanisms.
Since nephrotic patients are edematous, should plasma volume
measurements be normalized per kilogram of dry or wet weight?
Depending on the approach chosen, a given absolute plasma
volume measurement could be considered to be increased (ad-
justed for dry weight) or decreased (adjusted for wet wt). To date
there is insufficient information to choose between these two
possibilities. Posture has also been found to be a determinant of
plasma volume measurement. Specifically, nephrotic patients with
normal plasma volume measurements in the supine position have
been found to have an exaggerated fall in plasma volume in the
orthostatic as compared to the recumbent positions [18, 19]. This
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hypovolemic effect has been suggested to explain the occurrence
of oliguric acute renal failure and hypovolemic shock, which has
been observed in some patients with nephrotic syndrome [20–24].
Studies assessing plasma volumes in nephrotic patients should
therefore be measured in both the supine and upright positions.
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Plasma volume expansion, as would occur with primary renal
sodium and water retention, would be expected to suppress the
renin-angiotensin-aldosterone system (RAAS). Moreover, glo-
merular diseases that cause the nephrotic syndrome might also be
associated with the syndrome of hyporeninemia and hypoaldoste-
ronism. However, in a review of nine studies, elevated plasma
renins were found in approximately 50% of the cases [10]. The
postural position must also be considered when measuring plasma
renin, since increased RAAS activity may only be demonstrable
when the patient is in an upright position. Angiotensin converting
enzyme inhibitors (ACEI), which are often used in nephrotic
patients, have been shown to significantly decrease plasma aldo-
sterone concentration, yet a natriuresis did not occur (Fig. 1). This
led the authors to conclude that aldosterone was not important in
the sodium retention of the nephrotic syndrome, thus supporting
the “overfill” hypothesis [25]. This conclusion, however, was
premature. Specifically, ACEI lowered blood pressure, and thus
renal perfusion pressure, by a mean of 10 mm Hg in the nephrotic
patients (Fig. 1). This hemodynamic effect could by itself cause an
antinatriuretic response and thus override any natriuretic re-
sponse secondary to the fall in plasma aldosterone. To test this
possibility, studies were performed in five nephrotic patients using
competitive inhibition of aldosterone with spironolactone [26]. In
order to ensure competitive inhibition of any elevation of endog-
enous aldosterone, large doses of spironolactone (200 mg orally
twice daily) were used. A control group of six normal subjects
were also studied using the same dose and duration of treatment
of spironolactone. In order to avoid any differences in sodium
balance, both the patients and control subjects received a constant
high sodium intake for four days prior to and four days during
spironolactone therapy. The results demonstrate a natriuretic
response to spironolactone only in the nephrotic patients (Fig. 2).
Since the natriuretic response to spironolactone is dependent on
an intact adrenal gland, it is reasonable to conclude that aldoste-
rone was contributing to sodium retention in these nephrotic
patients. These results, therefore, support the underfill rather
than the overfill hypothesis of sodium retention in nephrotic
patients. The earlier finding in experimental nephrotic syndrome
that adrenalectomy diminishes sodium retention [27] is also
compatible with these spironolactone results [26].
It is also important to emphasize that assessment of the RAAS
activity can only be undertaken in relationship to sodium balance.
Thus, plasma renin and/or aldosterone concentration in an edem-
atous nephrotic patient with a large positive sodium balance
should be suppressed, which means that the “normal” level is
relatively increased.
Since most of the plasma renin and aldosterone concentrations
reported in patients with nephrotic syndrome have not been
Fig. 1. Effect of captopril on blood pressure, mean plasma aldosterone
levels and 24 hr urinary sodium excretion in patients with the nephrotic
syndrome. (Modified from Brown et al [25], and used with permission of
S. Karger Ag, Basel, Switzerland.)
Fig. 2. Sodium excretion of both nephrotic patients and controls on a
constant sodium intake of 285 6 6 mEq/day before and after spironolac-
tone (200 mg, po., b.i.d.) was given. Reprinted with permission from
Williams & Wilkins (Shapiro MD, Hasbargen J, Hensen J, Schrier RW:
Role of aldosterone in the sodium retention of patients with the nephrotic
syndrome. Am J Nephrol 10:44–48, 1990 [26]).
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correlated with total body sodium balance, plasma concentrations
in nephrotic patients that fall within the normal range for control
subjects should not be used in support of the overfill hypothesis.
Moreover, similar plasma concentrations of renin and aldosterone
before and after a steroid-induced natriuresis do not negate the
role of the RAAS since, because of changes in total body sodium
balances, these hormonal concentrations are not comparable. The
renal interstitial edema and the resultant effect on the RAAS is
another changing variable before and after edema remission in
nephrotic patients.
SYMPATHETIC NERVOUS SYSTEM
Plasma and urinary catecholamine concentrations have been
found to be increased in patients with the nephrotic syndrome
[28–30], a finding more compatible with the underfill rather than
the overfill hypothesis of sodium and water retention. Recent
studies examining catecholamine kinetics in control subjects and
nephrotic patients have also shown an increased turnover in
nephrotic patients (Fig. 3). The results are, however, more
variable in experimental models of the nephrotic syndrome. The
demonstration that renal denervation ameliorates sodium and
water retention in an experimental model of nephrotic syndrome
supports a role of the sympathetic nervous system in the associ-
ated edema formation (Fig. 4) [31]. In the same model renal
denervation also reversed the resistance to atrial natriuretc pep-
tide [31]. This increased renal sympathetic tone is most compat-
ible with hypovolemia in this model of nephrotic syndrome. A
recent study has also shown that nephrotic rats have a central
defect in cardiac baroreflex function that is specific for efferent
renal sympathetic nerve activity [32] and is reversed with an
angiotensin II receptor antagonist [33]. It has been suggested,
therefore, that the activation of the renin-angiotensin-aldosterone
system secondary to an underfilled circulation may impair barore-
ceptor integrity [32]. These human and experimental studies in
the nephrotic syndrome support an underfilled circulation with
associated stimulation of the sympathetic nervous system. On the
other hand, puromycin-induced nephrotic rats demonstrated a
persistent defect in renal sodium excretion in the isolated per-
fused kidney [34]. Moreover, bilateral renal denervation in rats
with adriamycin-induced nephrotic syndrome did not correct the
impaired response to volume expansion [35]. The results from the
latter two studies are most compatible with overfill edema.
ARGININE VASOPRESSIN
Plasma volume expansion should suppress and plasma volume
depletion should increase the non-osmotic release of arginine
Fig. 3. Supine plasma norepinephrine
secretion (a) and clearance rates (b) in patients
with the nephrotic syndrome and in controls.
Significantly greater secretion rates but not
clearance rates are seen in nephrotic patients
compared to controls (P , 0.05). Reprinted
with permission from Williams & Wilkins
(Rahman SN, Abraham WT, Van Putten VJ,
Hasbargen JA, Schrier RW: Increased
norepinephrine secretion in patients with the
nephrotic syndrome and normal glomerular
filtration rates: Evidence for primary
sympathetic activation. Am J Nephrol 13:266–
270, 1993 [30]).
Fig. 4. Renal denervation in nephrotic rats (DNX) ameliorates the
sodium and water retention compared to sham (SHAM) operated rats.
Sodium and water excretion in denervated rats was similar to controls.
Reprinted with permission from the American Journal of Physiology
(DiBona GF, Herman PJ, Sawin LL: Neural control of renal function in
edema-forming states. Am J Physiol 254:R1017—R1024, 1988 [31]).
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vasopressin (AVP). Several studies support a role for AVP in the
water retention found in the nephrotic syndrome [36, 37]. Usberti
et al demonstrated a direct correlation between the decrement in
plasma volume and plasma AVP concentrations in patients with
the nephrotic syndrome (Fig. 5) [36]. Elevated plasma vasopressin
concentrations have also been observed in puromycin-induced
nephrotic syndrome in the rat [37].
RESPONSE TO PLASMA VOLUME EXPANSION
An argument for overfill edema secondary to an intrarenal
sodium retaining defect in nephrotic patients is the finding that
plasma volume expansion with saline, hyperoncotic or isoncotic
albumin or head-out water immersion (HWI) improves, but does
not normalize sodium excretion in the nephrotic patient. The
authors reason that if underfill is the primary reason for sodium
and water retention in nephrotic syndrome, normalizing plasma
volume should totally correct the perturbation in renal sodium
and water excretion. While this may seem like a reasonable
conclusion, there is an alternative explanation. It has been known
for many years that prior sodium restriction blunts and prior
sodium excess enhances the natriuretic response to volume ex-
pansion [38]. Thus, one might expect a blunted natriuretic re-
sponse to volume expansion in nephrotic patients whose circula-
tion is underfilled. This alternative interpretation for the failure to
totally normalize sodium excretion during volume expansion in
the nephrotic patient is, therefore, also reasonable. On the other
hand, patients with nephrotic syndrome who are overfilled or
volume expanded would also not be expected to normally excrete
a sodium load because of primary renal sodium retention. An
intrarenal defect has indeed been shown with toxic experimental
nephrotic syndrome in the rat [39]. This defect has been localized
to the collecting duct using micropuncture techniques in superfi-
cial nephrons (Fig. 6). Studies in humans with nephrotic syndrome
also support enhanced collecting duct sodium reabsorption, since
the action of aldosterone on the collecting duct can be reversed by
high dose spironolactone. This effect of aldosterone, however, is
presumably due to underfilling activating the RAAS, thus result-
ing in secondary, not primary, renal sodium retention.
Fig. 5. Relationship between plasma ADH and blood volume (BV) in
nephrotic subjects. y 5 15.47 2 0.17x; r 5 20.722; P , 0.001. (Reprinted
with permission from authors and the International Society of Nephrology
[36].) Different symbols indicate known course of nephrotic syndrome.
Fig. 6. Schematic representation of sodium delivery and reabsorption
along superficial nephron segments in puroaminonucleoside (PAN)-
perfused kidneys. Sodium excretion is reduced in the puromycin-perfused
kidney. (Reproduced from The Journal of Clinical Investigation, 1983, vol
71, p. 97, by copyright permission of the American Society for Clinical
Investigation [40].)
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COMPENSATORY MECHANISMS AGAINST HYPO-
ONCOTIC-RELATED EDEMA
There are compensatory mechanisms whereby interstitial
edema may not accompany a lowered plasma albumin concentra-
tion and capillary oncotic pressure. Specifically, increased trans-
capillary transport of fluid is initially accompanied by a rise in
interstitial pressure and increased lymphatic flow, which can
counterbalance the effect of the lowered capillary oncotic pres-
sure of the nephrotic syndrome, thereby avoiding edema forma-
tion. Moreover, as transport of fluid into the interstitium occurs in
association with hypoalbuminemia, the interstitial oncotic pres-
sure falls in parallel with the plasma oncotic pressure. A new
steady-state may, therefore, occur without a decrease in the
average 12 mm Hg transcapillary oncotic gradient (plasma vs.
interstitial oncotic pressure: 24 minus 12 mm Hg). There is also
evidence that the capillary permeability to protein may decrease
in response to hypoalbuminemia, thereby further protecting
plasma oncotic pressure [40]. Studies in nephrotic patients that
demonstrate equivalent changes in plasma and interstitial protein
concentration during both relapse and remission also support the
conclusion that compensatory mechanisms are adequate to avoid
hypoalbuminemia-induced edema (Fig. 7) [41]. Such a conclusion
is supported by the report that patients with analbuminemia do
not develop anascara [42–45]. Thus, an intrarenal sodium-retain-
ing defect independent of plasma oncotic pressure could account
for volume expansion (overfill) in the hypoalbuminemic nephrotic
patient. Such reasoning must, however, reckon with the observa-
tion that several circumstances that cause hypoalbuminemia with-
out renal involvement can be associated with anasarca. Specifi-
cally, protein-losing gastroenteropathy or dermopathy as well as
Kwashiorkor’s syndrome can be associated with severe hypoalbu-
minemia and profound edema. These clinical states that occur in
the absence of primary renal sodium retention suggest that the
compensatory responses to a lowered capillary oncotic pressure
do not always prevent interstitial edema formation in extreme
cases (such as plasma albumin concentration , 2.0 g/dl). It is also
important to point out that analbuminemic patients generally do
have mild edema and also may hyperexcrete a sodium load, thus
providing another mode of protection against edema formation
[42].
It has been suggested that compensatory mechanisms to pre-
vent interstitial edema may already be overwhelmed in the
nephrotic patient, and this may explain why comparable volume
expansion causes hypertension in normoalbuminemic patients
with renal disease but not hypoalbuminemic nephrotic patients [1,
46]. The proposed explanation is that nephrotic patients have
exhausted their compensatory capillary reserve mechanisms
against edema, and therefore the administered fluid moves rapidly
into the interstitium rather than remaining in the intravascular
compartment and causing hypertension. An alternative or addi-
tional explanation is that the nephrotic patient’s vascular com-
partment is underfilled in comparison to the normoalbuminemic
chronic renal failure patient. Thus, for the same volume load, the
nephrotic patients are less likely to become plasma volume
expanded and hypertensive.
TOXIC MODELS OF NEPHROTIC SYNDROME IN
ANIMALS
An additional caveat must be stated about toxic models of the
nephrotic syndrome induced by either adriamycin or puromycin.
In addition to the glomerular capillary leak of protein, numerous
tubular defects have now been observed, suggesting that extrap-
olation of results from these toxic models to humans should be
made with caution.
FUTURE CONSIDERATIONS
In summary, the purpose of this editorial is not to provide a
comprehensive review, but rather to give some pause to the
conclusion that the “majority” of nephrotic patients are overfilled
(that is, plasma volume expanded) due to primary renal sodium
retention. While overfill edema may occur in the nephrotic
syndrome, there are a number of caveats before the “majority” of
nephrotic patients are considered to have overfill edema. Given
these caveats raised in this critique, at the present time it may be
more appropriate to state that “some” rather than the “majority”
of patients with the nephrotic syndrome have plasma volume
expansion secondary to primary renal sodium retention, which
causes overfill edema. The clinical implications of the so-called
overfill versus underfill edema of nephrotic syndrome are substan-
tial. If the majority of nephrotic patients with a normal GFR are
indeed plasma volume expanded, the edema can be beneficially
treated aggressively with diuretics without potential complica-
tions. The diuretics would override the primary renal sodium
Fig. 7. Relationship between plasma and tissue-fluid oncotic pressure
(COP) in 12 patients with the nephrotic syndrome, at the first visit (E)
and during follow up of six patients (F). (Reprinted with permission from
Nephron [42].)
Table 1. Factors that may give guidance as to whether in an individual
patient with the nephrotic syndrome has overfill of underfill edema
Overfill Underfill
GFR ,50% of normal 1 2
GFR .75% of normal 2 1
Serum albumin .2 g/dl 1 2
Serum albumin ,2 g/dl 2 1
Histology minimal change 2 1
Hypertension 1 2
Postural hypotension 2 1
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retention and the discussed compensatory mechanisms of hy-
poalbuminemia will prevent edema formation. On the other hand,
if the majority of these patients are underfilled, diuretic treatment
must be more judiciously undertaken to avoid further depletion of
intravascular volume and even acute renal failure. The assessment
of intravascular volume of an individual patient with the nephrotic
syndrome is thus difficult, but critical in the decision of whether it
is safe to aggressively use diuretics. In Table 1 factors are detailed
that may assist in this clinical decision. In closing, a historical
event is probably worth remembering. Specifically, in earlier
studies plasma volume depletion was not detectable with chronic
thiazide treatment; thus, it was concluded for quite some time that
the drug’s antihypertensive effect was independent of a negative
sodium balance. We now know that this is not the case, since once
the diuretic is discontinued the patients uniformly retain sodium.
Therefore, an assumed sensitivity of plasma volume measure-
ments misled investigators for quite some time. It is certainly
worth emphasizing that conclusions based on plasma volume
measurements in nephrotic patients and extrapolation of results
from toxic animal models of nephrotic syndrome with multiple
tubular defects to humans must be made with caution. We believe
that further studies in patients with nephrotic syndrome are
necessary to better understand the mechanisms of the sodium and
water retention and edema formation.
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